博济医药收盘下跌2.20%，滚动市盈率210.74倍，总市值34.06亿元

Core Viewpoint - Boji Pharmaceutical's stock closed at 8.89 yuan, down 2.20%, with a rolling PE ratio of 210.74 times, significantly higher than the industry average of 40.82 times [1][2] Company Overview - Boji Pharmaceutical provides comprehensive "one-stop" CRO services for domestic and international pharmaceutical companies and research institutions, focusing on new drug and medical device development [1] - The company's main products include clinical research services, preclinical research services, independent preclinical R&D, and other consulting services [1] Financial Performance - In Q1 2025, the company reported revenue of 139 million yuan, a year-on-year decrease of 17.06%, and a net profit of 3.90 million yuan, down 76.38% [2] - The sales gross margin stood at 30.60% [2] Shareholder Information - As of March 31, 2025, Boji Pharmaceutical had 26,693 shareholders, an increase of 2,742 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Industry Comparison - Boji Pharmaceutical ranks 43rd in the medical services industry based on PE ratio, with the industry median at 45.93 times and the average at 40.82 times [1][2] - The company has received several accolades, including being ranked 8th among the top 20 CRO companies in China for 2024 and recognized in various industry events [1]